Partnering & licensing

At Nabla, we welcome opportunities to partner our platform to enable drug design against difficult targets, like multipass membrane proteins. We specialize in designing drugs that can access limited epitopes and are target and conformation selective.

Nabla has a growing collection of high quality biologics against a variety of challenging disease targets. We are excited by the opportunity to license these molecules to experienced drug development partners to maximize the chance of patient impact.